Welcome to our dedicated page for Cemtrex SEC filings (Ticker: CETX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cemtrex, Inc. (CETX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Cemtrex is a diversified industrial and technology company with Security, Industrial, and Aerospace & Defense segments, and its filings offer detailed information on capital structure, acquisitions, and corporate actions that affect CETX shareholders.
Among the key documents are Form 8-K current reports, where Cemtrex discloses material events. Recent 8-K filings describe a 1-for-15 reverse stock split approved by the board to address Nasdaq listing requirements, a promissory note with Streeterville Capital, LLC used to fund potential acquisitions, and a share purchase agreement to acquire Invocon, Inc., a systems-engineering firm in aerospace and defense. Another 8-K details a securities purchase agreement for a registered direct offering of common stock and pre-funded warrants, including gross proceeds and closing terms.
Investors can also review filings related to equity and preferred stock, such as disclosures on Series 1 Preferred Stock dividends paid in additional preferred shares, and unregistered sales of equity securities. These documents explain dividend terms, preference amounts, and how preferred stock fits into Cemtrex’s capital structure.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand items such as reverse stock split mechanics, acquisition agreements, and financing terms. Real-time updates from the SEC’s EDGAR system ensure that new CETX filings, including future 10-K annual reports, 10-Q quarterly reports, and Form 4 insider transaction reports when available, are added promptly.
By using this page, investors can study Cemtrex’s official disclosures on acquisitions, financing arrangements, stock splits, and preferred stock dividends, while AI-generated insights help clarify complex legal and financial language.
Cemtrex Inc. entered into a Securities Purchase Agreement on January 9, 2026 with a single accredited institutional investor for a registered direct offering of common stock and pre-funded warrants. The company agreed to issue and sell securities for aggregate gross proceeds of $4,000,000.
The offering closed the same day. Cemtrex issued 400,000 shares of common stock and pre-funded warrants to purchase 1,069,507 shares of common stock. The agreement includes customary representations, warranties, and covenants. Cemtrex also filed the form of pre-funded warrant, the purchase agreement, a legal opinion from The Doney Law Firm, and a press release announcing the offering as exhibits.
Cemtrex, Inc. has completed its previously announced acquisition of Invocon, Inc. On January 8, 2026, the company closed the share purchase agreement signed on November 13, 2025, buying 100% of Invocon’s outstanding shares for $7,060,000 in cash, paid at closing. Following the transaction, Invocon became a wholly-owned subsidiary of Cemtrex.
The filing notes that the detailed share purchase agreement was previously filed and that its representations and warranties primarily allocate risk between the parties. Cemtrex plans to file Invocon’s financial statements and required pro forma financial information by amendment within 71 calendar days of the required filing date. Cemtrex also issued a press release announcing the completion of the acquisition, furnished as Exhibit 99.1.
Cemtrex Inc. entered into a Securities Purchase Agreement with a single accredited institutional investor for a registered direct offering generating aggregate gross proceeds of $2,000,000. The transaction involved the sale of common equity and pre-funded warrants to that investor.
The offering closed on December 11, 2025, with Cemtrex issuing 310,000 shares of common stock and pre-funded warrants to purchase 356,667 additional shares of common stock. Legal counsel The Doney Law Firm delivered an opinion on the legality of the securities, and Cemtrex issued a press release describing the offering, which is included as an exhibit.
Cemtrex is conducting a registered direct offering of up to $2,000,000 of common stock or pre-funded warrants to a single accredited institutional investor. Shares are priced at $3.00, or $2.999 per pre-funded warrant with a $0.001 exercise price and a 4.99% beneficial ownership cap, for up to 666,667 shares or equivalent. There is no underwriter, and net proceeds are estimated at approximately $1,950,000.
The company plans to use the cash for working capital and general corporate purposes, including potential acquisitions. As of December 10, 2025, 6,217,047 shares of common stock were outstanding, and the stock trades on the Nasdaq Capital Market under the symbol CETX.
The filing also underscores elevated risk: Cemtrex reports recent operating losses, near-term debt obligations of $12,067,849 and working capital of $4,916,624, and its auditor’s report includes a going concern paragraph. Management highlights reliance on prior equity raises, a $7,025,000 secured convertible note issued in November 2025, and a 1-for-15 reverse stock split completed on September 29, 2025 to support liquidity and Nasdaq listing, while warning of potential further dilution and ongoing listing compliance challenges.
Cemtrex, Inc. entered into a Share Purchase Agreement to acquire 100% of the issued and outstanding shares of Invocon, Inc., a Texas-based systems‑engineering firm, for a purchase price of $7,060,000. The transaction is expected to close on or around January 1, 2026, and is contingent on customary closing conditions.
Invocon provides turnkey solutions for demanding applications in extreme environments across aerospace, defense, and civil structure monitoring, serving major corporations, government entities, and universities. After the acquisition is completed, Cemtrex plans to create a new reporting segment called Aerospace & Defense, signaling a formal expansion into this end market.
Cemtrex, Inc. entered a material definitive agreement, issuing a promissory note to Streeterville Capital, LLC with an original principal of $7,025,000. After $25,000 in original issuance fees, the company received $7,000,000 in cash.
Interest accrues at the daily SOFR rate from November 7, 2025 through December 31, 2025, then at 8% per annum beginning January 1, 2026. If the note remains outstanding on January 1, 2026, a one-time additional interest fee of $1,050,000 will be added to the balance. The note matures eighteen months from issuance, with redemptions starting six months after issuance. Cemtrex states it intends to use the cash proceeds to complete potential acquisitions.
Cemtrex Inc. is implementing a 1-for-15 reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on September 29, 2025. The stock will begin trading on a split-adjusted basis that day under the same trading symbol, CETX, with a new CUSIP number 15130G873.
As of this filing, Cemtrex has 11,084,809 shares of common stock outstanding, which will be reduced to roughly one-fifteenth of that amount after the split, subject to rounding of fractional shares. The reverse split was approved earlier by stockholders and is intended to help the company regain compliance with Nasdaq’s minimum $1.00 bid price requirement.
Most options, warrants, and equity awards will be proportionately adjusted so that holders keep essentially the same aggregate exercise price. However, Cemtrex discloses that its Adjustable Warrants, currently exercisable for 15,412,956 shares at an exercise price of $0.5737 per share, contain provisions that will reduce the post-split exercise price and significantly increase the number of underlying shares, while keeping the total exercise price the same.
Cemtrex Inc. reported that its board of directors approved payment of the upcoming dividend on its Series 1 Preferred Stock in additional shares of the same Series 1 Preferred Stock rather than in cash. The new shares are expected to be issued on October 7, 2025 to holders of record as of the close of business on September 30, 2025.
Holders of the Series 1 Preferred Stock are entitled to receive dividends at a 10% annual rate, based on a $10.00 per share preference amount, with dividends payable on a semiannual schedule.
CEMTREX Inc. is the subject of a jointly filed Schedule 13G/A by three Altium-related reporting persons that discloses no reportable stake in the company’s common stock. The filing names Altium Healthcare Long Short Onshore Fund LP, Altium Capital Management LLC and Altium Healthcare Long Short GP LLC and states the Fund as the record and direct beneficial owner of the securities covered by the statement while simultaneously reporting an aggregate beneficial ownership of 0 shares (0% of the class). The filers note they may be deemed members of a group for regulatory purposes but expressly state the filing is not an admission of beneficial ownership or of acting to acquire or influence control. The statement also includes a certification that the securities were not acquired to influence control.
This Schedule 13G/A discloses that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC (the Reporting Persons) are each deemed to beneficially own 336,801 shares of Cemtrex Inc. common stock, representing approximately 9.99% of the company’s outstanding common stock as presented in the filing. The shares reported are issuable upon exercise of a warrant held by Intracoastal (Intracoastal Warrant 1).
Each Reporting Person has shared voting and shared dispositive power over 336,801 shares and no sole voting or dispositive power. The filing explains that blocker provisions in Intracoastal Warrant 1 and Intracoastal Warrant 2 prevent exercise to the extent doing so would increase ownership above 9.99% and 4.99%, respectively, thereby excluding 1,671,598 and 142,778 warrant shares from current beneficial ownership calculations. Without those blocker provisions, the Reporting Persons may be deemed to beneficially own 2,151,177 shares.